General Catalyst

General Catalyst Group Management, LLC is a private equity and venture capital firm founded in 2000 and based in Cambridge, Massachusetts, with additional offices in North America and Europe. The firm specializes in early-stage and growth equity investments, focusing on a wide range of technology sectors, including advanced materials, clean energy, disruptive technology, healthcare IT, and consumer services, among others. General Catalyst typically invests between $0.05 million and $0.25 million in seed-stage companies and between $10 million and $50 million in growth equity, seeking profitable firms with substantial revenue and EBITDA. Their approach emphasizes mentorship and collaboration, fostering strong relationships with entrepreneurs who share their vision and values. They have managed eight venture capital funds, accumulating around $3.75 billion in capital commitments, reflecting their commitment to supporting innovative companies throughout their growth journey.

Adrian Abeijon

Investor

Mark Allen

CFO

Juliet Bailin

Principal

Brian Bedol

Managing Director

Marc Bhargava

Managing Director

Chris Bischoff

Managing Director

Larry Bohn

Managing Director

Kristen Camarota

Investor

Kenneth Chenault

Chairman and Managing Director

Quentin Clark

Managing Director

Mark Crane

Partner, Investment Team

Joel Cutler

Co-Founder and Managing Director

Christopher Davis

Partner, Investments

Kyle Doherty

Managing Director, Investments

Bill Fitzgerald

Co-Founder and Special Advisors

Molly Blaauw Gillis

Partner and Chief of Staff

Jeremy Goldstein

Partner

Julia Goodman

Investor

Drew Gordon

Investor

Steve Herrod

Managing Director

Tony Ho

Investor

Diana Hong

Investor

Mina Hsiang

Associate

Paula Hübner

Partner

Nmachi Jidenma

Partner

Christopher Kauffman

Principal and Member of the Investment Team

Zak Kukoff

Principal

Bill Kung

Principal

Paul Kwan

Managing Director

Alexandre Momeni

Executive, Investments and Partner

Deep Nishar

Managing Director

Dipchand ("Deep") Nishar

Managing Director

Reva Nohria

Principal

Trevor Oelschig

Managing Director

Pranay Orugunta

Healthcare Investor

Mo Punjwani

Associate, Investments

Candace Richardson

Principal

Max Rimpel

Partner

Paul Sagan

Investor

Pranav Singhvi

Managing Director

Vedant Suri

Investor

Alex Tran

Managing Director

Catherine Tu

Partner

Elena Viboch

Partner

Andrea Wang

Principal, Early Stage Investment

Vincent Zhu

Investor

Past deals in CMS

OM1

Series D in 2021
OM1, Inc. is a digital health company that develops a platform aimed at measuring and forecasting patient outcomes data for healthcare organizations. The platform supports hospitals and health systems in meeting requirements for patient-reported and clinical outcomes, particularly in value-based care programs and bundle payments. By leveraging advanced analytics, the platform provides predictive and prescriptive insights that help mitigate risks and reduce costs while demonstrating outcomes to various stakeholders. OM1's technology synthesizes and enriches clinical data to offer AI-driven insights that enhance clinical, financial, and operational management, thereby establishing a new standard for health outcomes information. Founded in 2014 and based in Boston, Massachusetts, OM1 was previously known as Better Outcomes Corporation.

OM1

Series C in 2019
OM1, Inc. is a digital health company that develops a platform aimed at measuring and forecasting patient outcomes data for healthcare organizations. The platform supports hospitals and health systems in meeting requirements for patient-reported and clinical outcomes, particularly in value-based care programs and bundle payments. By leveraging advanced analytics, the platform provides predictive and prescriptive insights that help mitigate risks and reduce costs while demonstrating outcomes to various stakeholders. OM1's technology synthesizes and enriches clinical data to offer AI-driven insights that enhance clinical, financial, and operational management, thereby establishing a new standard for health outcomes information. Founded in 2014 and based in Boston, Massachusetts, OM1 was previously known as Better Outcomes Corporation.

OM1

Series B in 2018
OM1, Inc. is a digital health company that develops a platform aimed at measuring and forecasting patient outcomes data for healthcare organizations. The platform supports hospitals and health systems in meeting requirements for patient-reported and clinical outcomes, particularly in value-based care programs and bundle payments. By leveraging advanced analytics, the platform provides predictive and prescriptive insights that help mitigate risks and reduce costs while demonstrating outcomes to various stakeholders. OM1's technology synthesizes and enriches clinical data to offer AI-driven insights that enhance clinical, financial, and operational management, thereby establishing a new standard for health outcomes information. Founded in 2014 and based in Boston, Massachusetts, OM1 was previously known as Better Outcomes Corporation.

OM1

Series A in 2017
OM1, Inc. is a digital health company that develops a platform aimed at measuring and forecasting patient outcomes data for healthcare organizations. The platform supports hospitals and health systems in meeting requirements for patient-reported and clinical outcomes, particularly in value-based care programs and bundle payments. By leveraging advanced analytics, the platform provides predictive and prescriptive insights that help mitigate risks and reduce costs while demonstrating outcomes to various stakeholders. OM1's technology synthesizes and enriches clinical data to offer AI-driven insights that enhance clinical, financial, and operational management, thereby establishing a new standard for health outcomes information. Founded in 2014 and based in Boston, Massachusetts, OM1 was previously known as Better Outcomes Corporation.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.